NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Inhibrx Biosciences, Inc. INBX
3 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$1.3M
▲ 550.0% vs FY2024
EPS · FY25
$-9.04
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-197.8%
Net margin · FY25
-10773.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.3M
Revenue, FY2025 · full 3-year series below
Revenue
Net income
The company lost 10773 cents on every revenue dollar this year.
Per share
USD -9.04
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-197.8%
Return on equity, FY2025
ROE
Operating margin-10386.5%
Net margin-10773.5%
Return on assets-85.6%
Each USD of equity lost 198 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 146.5M
total assets, end of FY2025
Total assetsUSD 146.5M
EquityUSD 8.0M
CashUSD 124.2M
Gross debtUSD 100.6M
Net debtUSD -23.7M
Current ratio3.93×
The company holds more cash than debt.
History
3 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
Revenue $B
0.0
0.0
0.0
Operating income $B
−0.1
−0.3
−0.2
EBITDA $B
−0.1
−0.3
−0.2
Income tax $B
0.0
0.0
0.0
Net income $B
−0.1
1.7
−0.2
EPS, diluted $
−9.04
112.62
−20.48
Dividend / sh $
·
·
·
Payout %
·
·
·
ROE %
−197.8
1905.9
−554.8
Shares out B
0.01
0.01
0.05
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
9 of 9
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed